ATC Group: L01EK03 Tivozanib

The World Health Organization's ATC classification organizes medical drugs based on therapeutic properties, chemical composition, and anatomy. It helps make essential medicines readily available globally and is widely used in the pharmaceutical industry.

Position of L01EK03 in the ATC hierarchy

Level Code Title
1 L Antineoplastic and immunomodulating agents
2 L01 Antineoplastic agents
3 L01E Protein kinase inhibitors
4 L01EK Vascular endothelial growth factor receptor (VEGFR) tyrosine kinase inhibitors
5 L01EK03

Active ingredients in L01EK03

Active Ingredient Description
Tivozanib

Tivozanib potently and selectively blocks all 3 Vascular Endothelial Growth Factor receptors (VEGFR) and has been shown to block various VEGF-induced biochemical and biologic responses in vitro. By blocking VEGF-induced VEGFR activation, tivozanib inhibits angiogenesis and vascular permeability in tumour tissues, leading to inhibition of tumour growth in vivo.

Related product monographs

Title Information Source Document Type  
FOTIVDA Hard capsule European Medicines Agency (EU) MPI, EU: SmPC

Medicines in this ATC group

Austria (AT)

Estonia (EE)

Finland (FI)

Ireland (IE)

Lithuania (LT)

Netherlands (NL)

New Zealand (NZ)

Poland (PL)

Romania (RO)

Spain (ES)

United Kingdom (UK)

Note the following: The list of brand names is continuously updated, and thus does not include the total of products circulating worldwide.